web analytics

Cantargia submits request for pre-IND meeting on CAN04 with US FDA

Cantargia AB today announce that a request for a pre-IND meeting with the US FDA has been submitted. The purpose of the meeting is to discuss the current documentation on the antibody CAN04 and a proposed new phase I clinical combination study with CAN04 and an immune checkpoint inhibitor under a US IND. The plan is to conduct this trial at clinical centers in the US.
Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). The antibody CAN04 binds IL1RAP with high affinity and functions through both ADCC and blockade of interleukin 1

Source: Cantargia submits request for pre-IND meeting on CAN04 with US FDA

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.